Viridian Therapeutics to Participate in June Investor Conferences

Rhea-AI Summary

Viridian Therapeutics (NASDAQ: VRDN) announced that CEO Jonathan Violin, Ph.D., will participate in two fireside chats at upcoming conferences in New York. The first is at the Jefferies Healthcare Conference on June 8, 2022, at 11:30 am ET, followed by the JMP Securities Life Sciences Conference on June 15, 2022, at 3:30 pm ET. Investors can access live webcasts of both events via registration links. Viridian focuses on innovative therapies for serious diseases, with its lead program targeting thyroid eye disease.

WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will participate in two fireside chats at the Jefferies Healthcare Conference being held in New York on June 8 -10, 2022 and the JMP Securities Life Sciences Conference in New York on June 15 - 16, 2022.

Jefferies Healthcare Conference
Format:	Fireside Chat
Date:	Wednesday, June 8
Time:	11:30 am ET
Webcast link:	Registration link

JMP Securities Life Sciences Conference
Format:	Fireside Chat
Date:	Wednesday, June 15
Time:	3:30 pm ET
Webcast link:	Registration link

The live webcast and a replay of the fireside chats can also be accessed under “Events” in the Investors section of the Viridian Therapeutics website.

About Viridian Therapeutics

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED). Viridian’s second product candidate, VRDN-002, is a distinct anti-IGF-1R antibody that incorporates half-life extension technology and is designed to support administration as a convenient, low-volume, subcutaneous injection. TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids. Viridian is based in Waltham, Massachusetts.

Investor and Media Contact
John Jordan
Viridian Therapeutics
Vice President, Investor Relations
& Corporate Communications
617-272-4691
IR@viridiantherapeutics.com

FAQ

When will Viridian Therapeutics participate in the Jefferies Healthcare Conference?

Viridian Therapeutics will participate in the Jefferies Healthcare Conference on June 8, 2022, at 11:30 am ET.

What is the date and time of the JMP Securities Life Sciences Conference for Viridian?

The JMP Securities Life Sciences Conference is on June 15, 2022, at 3:30 pm ET.

How can I watch the fireside chats featuring Viridian's CEO?

You can watch the fireside chats by registering through the provided webcast links for each conference.

What is the focus of Viridian Therapeutics as a biotechnology company?

Viridian Therapeutics focuses on advancing treatments for patients suffering from serious diseases underserved by current therapies, particularly thyroid eye disease.

What product candidate is Viridian's most advanced program?

Viridian's most advanced program is VRDN-001, a monoclonal antibody targeting the insulin-like growth factor-1 receptor.